Infusions take approximately 1 hour, but preparation time before and observation time after the infusion may vary. How often it happens For the first 3 infusions, BENLYSTA is given once every 2 weeks. After that, BENLYSTA is given once every 4 weeks. ...
and infusion-related reactions. Be aware of the risk of hypersensitivity reactions, which may present as infusion-related reactions. Discontinue immediately in the event of a serious reaction. With intravenous administration, if an infusion reaction develops, slow or interrupt the infusion. ...
Dosage form:single-dose vial for intravenous infusion, prefilled syringe for subcutaneous use, prefilled autoinjector for subcutaneous use Drug class:Selective immunosuppressants Medically reviewed byCarmen Pope, BPharm. Last updated on Nov 8, 2024. ...
注射用贝利尤单抗 Belimumab powder for concentrate for solution for infusion 商品名称: 【成分】 主要成份:贝利尤单抗 辅料:枸橼酸一水合物、枸橼酸钠二水合物、蔗糖和聚山梨酯80 【性状】白色至类白色饼状物。 【适应症】 本品与常规治疗联合,适用于在常规治疗基础上仍具有高疾病活动(例如:抗ds-DNA抗体阳性及...
The Canadian label for Benlysta [belimumab] has been updated to warn about the associated risks of hypersensitivity and infusion reactions. GlaxoSmithKline (GSK) issued a 'Dear Healthcare Professional' letter to say that new safety information has been added to the Canadian Product Monograph for ...
and death, reported; events generally occurred within hours of infusion; however, they may occur later; non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema reported and typically occurred up to a week following the most recent infusion ...
infusion solution for patients whose body weight is less than or equal to 40 kg, a 100 mL bag or bottle of normal saline, half-normal saline, or Lactated Ringer’s Injection may be used such that the resulting belimumab concentration in the infusion bag does not exceed 4 mg/mL. From ...
奔麗生凍晶注射劑.BenlystaPowderforSolutionforInfusion.Belimumab.衛署菌疫輸字第000935號.本藥限由醫師使用.定性與定量組成.每瓶含有120mg或400 ...。
infusion. Patients with a history of multiple drug allergies or significant hypersensitivity may be at increased risk. Premedication may mitigate or mask an infusion reaction or hypersensitivity response. In the controlled trial of BENLYSTA SC in adults, systemic h...
infusion. Patients with a history of multiple drug allergies or significant hypersensitivity may be at increased risk. Premedication may mitigate or mask an infusion reaction or hypersensitivity response. In the controlled trial of BENLYSTA SC in adults, ...